Clinical Trial Update: Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is exploring factors that influence immunotherapy response in mismatch repair-deficient or MSI-H gastric and gastroesophageal junction …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Gastric / Gastroesophageal Junction Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors | Phase 2 | Status: NOT_YET_RECRUITING